Artificial neural networks for decision-making in urologic oncology

被引:75
作者
Anagnostou, T
Remzi, M
Lykourinas, M
Djavan, D
机构
[1] Univ Vienna, Dept Urol, A-1090 Vienna, Austria
[2] Athens Gen Hosp G Gennimatas, Dept Urol, Athens, Greece
关键词
Artificial Neural Networks; ANN; urology; prostate cancer; diagnosis; staging; prognosis; treatment; recurrence;
D O I
10.1016/S0302-2838(03)00133-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The authors are presenting a thorough introduction in Artificial Neural Networks (ANNs) and their contribution to modem Urologic Oncology. The article covers a description of Artificial Neural Network methodology and points out the differences of Artificial Intelligence to traditional statistic models in terms of serving patients and clinicians, in a different way than current statistical analysis. Since Artificial Intelligence is not yet fully understood by many practicing clinicians, the authors have reviewed a careful selection of articles in order to explore the clinical benefit of Artificial Intelligence applications in modem Urology questions and decision-making. The data are from real patients and reflect attempts to achieve more accurate diagnosis and prognosis, especially in prostate cancer that stands as a good example of difficult decision-making in everyday practice. Experience from current use of Artificial Intelligence is also being discussed, and the authors address future developments as well as potential problems such as medical record quality, precautions in using ANN's or resistance to system use, in an attempt to point out future demands and the need for common standards. The authors conclude that both methods should continue to be used in a complementary manner. ANNs still do not prove always better as to replace standard statistical analysis as the method of choice in interpreting medical data. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:596 / 603
页数:8
相关论文
共 52 条
[1]   THE DISTRIBUTION OF PROSTATE SPECIFIC ANTIGEN IN MEN WITHOUT CLINICAL OR PATHOLOGICAL EVIDENCE OF PROSTATE-CANCER - RELATIONSHIP TO GLAND VOLUME AND AGE [J].
BABAIAN, RJ ;
MIYASHITA, H ;
EVANS, RB ;
RAMIREZ, EI .
JOURNAL OF UROLOGY, 1992, 147 (03) :837-840
[2]   Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml [J].
Babaian, RJ ;
Fritsche, H ;
Ayala, A ;
Bhadkamkar, V ;
Johnston, DA ;
Naccarato, W ;
Zhang, Z .
UROLOGY, 2000, 56 (06) :1000-1006
[3]  
BABAIAN RJ, 1997, COMP PROSTASURE INDE
[4]  
Barnhill Stephen D., 1997, Journal of Urology, V157, P63
[5]   Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer [J].
Batuello, JT ;
Gamito, EJ ;
Crawford, ED ;
Han, M ;
Partin, AW ;
McLeod, DG ;
O'Donnell, C .
UROLOGY, 2001, 57 (03) :481-485
[6]   Prostate-specific antigen density [J].
Beduschi, MC ;
Oesterling, JE .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :323-&
[7]  
Blute ML, 1998, CANCER, V82, P902, DOI 10.1002/(SICI)1097-0142(19980301)82:5<902::AID-CNCR15>3.0.CO
[8]  
2-4
[9]   Prostate-specific antigen velocity and repeated measures of prostate-specific antigen [J].
Carter, HB ;
Pearson, JD .
UROLOGIC CLINICS OF NORTH AMERICA, 1997, 24 (02) :333-&
[10]  
Dayhoff JE, 2001, CANCER, V91, P1615, DOI 10.1002/1097-0142(20010415)91:8+<1615::AID-CNCR1175>3.0.CO